Outpace Bio, a Seattle-based cell therapy company specializing in AI-powered protein design to enhance immune cell function in patients with solid tumors, has secured $144 million in Series B financing. This round brings the company’s total capital raised to approximately $200 million.
The Series B round was led by RA Capital Management, with participation from new investors including Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, and Alexandria Venture Investments, among others. Existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, WRF Capital, and Sahsen Ventures also contributed. Jake Simson, PhD, Partner at RA Capital Management, has joined the company’s Board of Directors.
Under the leadership of Marc Lajoie, PhD, Co-Founder and CEO, Outpace Bio is developing an internal pipeline of engineered T cell therapies for solid tumors. The proceeds from this financing will be used to advance multiple programmed T cell product candidates to early clinical proof-of-concept stages for solid tumor treatment.
Outpace Bio’s lead program, OPB-101, is a mesothelin-specific chimeric antigen receptor (CAR) T cell therapy enhanced by the company’s proprietary OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™ technologies. OPB-101 is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The funds will also support the expansion of Outpace Bio’s future pipeline using the company’s plug-and-play technology platform.
